Obermatt
See Similar Stocks →

RAPT Therapeutics

NMQ:RAPT · US75382E2081
BiotechnologySmall

360° View

no current rank
Price/Sales—
Price/Earnings91
Price/Book27
Dividend Yield1
Revenue Growth—
Profit Growth45
Capital Growth13
TSR 52w100
Leverage64
Liquidity63
Refinancing85
Combined—
Analyst Opinions1
Pro Holdings1
Opinion Changes2
Market Pulse1

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePrivate Company
ExchangeNASDAQGM
Founded2015
Employees68
Websiterapt.com
ISINUS75382E2081
Last UpdateApr 2, 2026
Index & Theme
InflammationImmunologyRespiratoryOncologyBiotechnologyMedicalPharmaceuticalTherapeutics

Description

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company. The company operates as a subsidiary of Bristol-Myers Squibb Company. The company focuses on discovering, developing and commercializing oral small mole…

Similar Stocks

The companies this stock is ranked against.

Compare RAPT Therapeutics with its peers
Unicycive Therapeutics
NAQ:UNCY
85
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Palvella Therapeutics
NAQ:PVLA
100
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Dianthus Therapeutics
NAQ:DNTH
20
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Shattuck Labs
NSQ:STTK
50
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →